Financial news

DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius expects mid-single digit organic growth in the medium-term, after strong investment year 2019 (english)

06/12/2018 - 22:30


Fresenius SE & Co. KGaA: Fresenius expects mid-single digit organic growth in the medium-term, after strong investment year 2019

^
DGAP-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Forecast
Fresenius SE & Co. KGaA: Fresenius expects mid-single digit organic growth
in the medium-term, after strong investment year 2019

06-Dec-2018 / 22:30 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation
(EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Fresenius expects mid-single digit organic growth in the medium-term, after
strong investment year 2019

Current Group expectations for FY 2019
Based on the current status of the Group's budget process and its FY 2018
guidance, Fresenius expects mid-single digit organic sales growth for FY
2019. Group net income1,2, however, is expected to be broadly stable over FY
2018. Fresenius continues to seek both sales growth and efficiency
improvement initiatives in order to enhance these expectations.

Current Group expectations
Given its current expectations for FY 2018 and FY 2019, Fresenius now
believes its ambitious Group targets for 2020 will not be met.

From 2020 onwards, Fresenius now expects sustainable organic Group sales
growth in the mid-single digits. Group net income2,3 is expected to grow
organically slightly faster than sales. Upon Fresenius Kabi's biosimilars
business breaking even, Fresenius expects an acceleration of Group earnings
growth. Unlike previous mid-term targets, these expectations exclude the
effect of small- to medium-sized acquisitions.

Fresenius will announce detailed FY 2019 financial guidance and mid-term
targets with the release of its FY 2018 results on February 20, 2019.

----------------------------------------
1 In constant currency, before special items and effects of IFRS 16, incl.
expenses for the further development of the biosimilars business, H1/18
adjusted for divestitures of Care Coordination activities. 2019 including
NxStage operating results.
2 Net income attributable to shareholders of Fresenius SE & Co. KGaA
3 Before special items

----------------------------------------

For additional information on the performance indicators used please refer
to our website at https://www.fresenius.com/alternative-performance-measures.

(Financial statements according to IFRS)

Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
The Management Board

Bad Homburg v.d.H., December 6, 2018

Contact:
Markus Georgi
Senior Vice President Investor Relations
T: +49 (0) 6172 608-2485
markus.georgi@fresenius.com

End of note


---------------------------------------------------------------------------

06-Dec-2018 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

   Language:    English
   Company:     Fresenius SE & Co. KGaA
                Else-Kröner-Straße 1
                61352 Bad Homburg v.d.H.
                Germany
   Phone:       +49 (0)6172 608-2485
   Fax:         +49 (0)6172 608-2488
   E-mail:      ir-fre@fresenius.com
   Internet:    www.fresenius.com
   ISIN:        DE0005785604
   WKN:         578560
   Indices:     DAX
   Listed:      Regulated Market in Dusseldorf, Frankfurt (Prime
                Standard), Munich; Regulated Unofficial Market in Berlin,
                Hamburg, Hanover, Stuttgart, Tradegate Exchange;
                Luxembourg Stock Exchange



   End of Announcement    DGAP News Service
---------------------------------------------------------------------------

755395 06-Dec-2018 CET/CEST

°

Weiterführende Inhalte

Weiterführende Inhalte